Vulvar Squamous Cell Carcinoma
Associated Genetic Biomarkers
NCI Definition: An invasive squamous cell carcinoma arising from the vulva. Risk factors include the human papilloma virus and cigarette smoking. Precursor lesions include the vulvar intraepithelial neoplasia, lichen sclerosus with associated squamous cell hyperplasia, and chronic granulomatous vulvar disease such as granuloma inguinale. Symptoms include vulvar pruritus or irritation, discharge, bleeding, and pain. The following morphologic variants have been identified: keratinizing, non-keratinizing, basaloid, warty, verrucous, keratoacanthoma-like, and squamous cell carcinoma with tumor giant cells. Risk factors for recurrence include advanced stage, tumor diameter greater than 2.5 cm, multifocality, capillary-like space involvement, associated vulvar intraepithelial neoplasia grades 2 or 3, and margins of resection involved by tumor. (WHO, 2003) 
There are 9 clinical trials for vulvar squamous cell carcinoma, of which 9 are open and 0 are completed or closed. Of the trials that contain vulvar squamous cell carcinoma as an inclusion criterion, 1 is phase 1 (1 open), 3 are phase 1/phase 2 (3 open), and 5 are phase 2 (5 open).
CDKN2A and HPV are the most frequent gene inclusion criteria for vulvar squamous cell carcinoma clinical trials .
Atezolizumab, cisplatin, and pembrolizumab are the most common interventions in vulvar squamous cell carcinoma clinical trials.
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.